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INTRODUCTION
Endometrial carcinoma is the most common type of uterine 
cancer and is a frequently seen gynecologic malignancy with 
breast cancer in developed countries. Patients with advanced 
or recurrent disease have poor prognosis sucha that it can 
be very hard to cure by surgery, conventional chemotherapy, 
radiation or a combination of these modalities. As some esti­
mate that the percent of women dying from endometrial car  ci­
noma has increased by 227% over the past decade, there is a 
great need to develop novel targeted agents that can be used 
alone or in combination with current treatment strategies [1].
Endometrial cancers are divided into two types (type I and 
type II) based on their biological, molecular and clinical para­
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Objective: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate 
the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies.
Methods: Imatinib mesylate (50 µM), lithium chloride (100 µM), medroxyprogesterone acetate (200 µM) and their combination 
were applied to monolayer and three dimensional cultures of human Ishikawa endometrial cancer for 72 hours. The cell prolife­
ra  tion index, apoptotic index, caspase­3 and midkine levels, cell cycle distributions in monolayer cultures and cell ultrastructure 
in spheroid cultures were evaluated. Results were statistically analyzed using the Student’s t­test.
Results: All drug applications inhibited cell proliferation (p<0.05), however the combination were the effective groups for 72 hours 
(p<0.05). Interestingly, although the loss of efficiency was seen higly seen every 24 hours at single applications, the inhibition rates of 
the combination groups were almost same for 72 hours. In concordance with these results, the apoptotic index, caspase­3 levels 
(p<0.05), cell morphology and ultrastructure damages were much higher in the combination groups. Imatinib mesylate induced 
S­phase arrest, however other groups induced G0+G1­phase arrest at 24 hours and all groups induced G0+G1 arrest at 72 hours 
(p<0.05). Imatinib mesylate and imatinib mesylate with medroxyprogesterone acetate induced highest decrease in midkine levels, 
respectively (p<0.05).
Conclusion: The present study showed that the combination of imatinib mesylate with lithium chloride and medroxyprogeste  rone 
acetate is highly active in Ishikawa endometrial carcinoma in vitro and the inhibition of midkine involved in their mechanism of 
action against endometrium defense.
Keywords: Endometrial cancer, Imatinib mesylate, Lithium chloride, Medroxyprogesterone acetate, Midkine
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meters [2]. Eighty percent of cases consist of type I or those 
tumors of endometrioid histology. Previous studies showed 
that they arise from persistent unopposed estrogen stimulation 
and in addition, they are generally estrogen receptor and pro­
gesterone receptor positive. The underlying mechani  sms can 
be listed as genetic alterations associated with these tumors 
include PTEN deletions or mutations (36­83%), microsatellite 
instability (20­40%), mutations of K­ras (15­30%) and gain of 
function mutations in β­catenin (25­40%) [3,4].
Imatinib mesylate (IM) also called Gleevec or STI571 is a well 
known tyrosine kinase inhibitor that has been used as a “magic 
bullet” for the treatment of leukemia and gastrointestinal tu­
mours. IM inhibits the activity of a number of receptor tyro  sine 
kinases as Abelson cytoplasmic tyrosine kinase (ABL), c­Kit, the 
platelet­derived growth factor receptor, and epi  dermal growth 
factor receptor (EGFR) [5]. Its success led the investiga  tors to 
search its antineoplastic effects on other cancer types includ­
ing endometrial cancer [6­9]. Previous reports that studied IM 
demonstrated that endometrial cancers which expressed IM 
targets respond to IM treatment and in these reports they also 
mentioned that IM should be used in combination in order to 
make the treatment more efficient [6,7].
Lithium chloride (LiCl) has been used clinically since the 19th 
century to treat psychotic diseases as bipolar disorders, and 
its safety profile is well documented. Previous studies showed 
that LiCl also possess antineoplastic effects in a variety of can­
cers including colorectal cancer [10], gastric cancer [11], and 
neuroblastoma [12]. It was shown that anti­neoplastic action 
of LiCl primarily depends on the inhibition of glycogen syn­
thase kinase 3­beta [13]. 
Medroxyprogesterone acetate (MPA) is a synthetic, orally active 
derivative of the natural steroid hormone progesterone, widely 
used in contraception of women/men and in oncology, both 
in the endocrine treatment of hormone­related cancers and as 
supportive therapy in the cachexia syndrome [14,15]. MPA is 
the only approved drugs in Europe for the clinical treatment 
of cancer­related anorexia/cachexia syndrome at the moment 
[16]. The anti­contraceptive and anti­neoplastic effects of MPA 
are the results of the anti­estrogenic action of MPA [17]. In the 
present study we focused on its antineoplastic effect. Wang et 
al. [18] proposed that Wnt/β­catenin signaling is activated by 
estrogen and inhibited by progesterone during the menstrual 
cycle. When this balanced is disrupted, the enhanced or unop­
posed estrogen signalling may lead to constitutive activation 
of Wnt/β­catenin signaling and this will trigger endometrial 
hyperplasia, which may develop further into endometrial can­
cer. In addition, the direct effect of enhanced or unopposed 
estrogen to nucleus through its receptor is the another reason 
for endometrial transformation to cancer.
Midkine (MDK), a newly pronounced old molecule, is a heparin­
binding growth factor playing a central role in carcinogenesis 
as an antiapoptotic and angiogenic factor. High expression of 
MDK in various human tumors and the success gained after 
inhibition of MDK make it a promising target for specific thera­
pies [19]. It has been proven to be involved in tumorigenesis 
of neuroblastoma, astrocytoma and malignant peripheral nerve 
sheath tumors and an elevated MDK expression has been detected 
in tumors such as the colon, lung, pancreas, stomach, esopha­
geal tumors, hepatocellular carcinoma, and endometrial car­
cinoma [19]. It was shown that treatment of normal endome­
trial cells by 17­beta oestradiol increased MDK levels [20]. 
In the present study we investigated whether LiCl and MPA 
can potentiate the cytotoxicity of IM in treatment of endo­
metrial cancer and the effect of MDK in these therapies. We 
targeted to treat both multiple diseases and increase life qual­
ity at same time. This means LiCl may increase IM cytotoxicity, 
treat another type of cancer (primary and secondary) and psy­
chiatric disorder as bipolar disorder at the same time, on the 
another side different from LiCl, MPA can also treat cancer­
related cachexia/anorexia and prevent pregnancy. 
MATERIALS AND METHODS
1. Monolayer cell culture 
Ishikawa cells (a generous gift from Uludag University, Bursa, 
Turkey) were routinely maintained in phenol­red­free RPMI 
1640 (Sigma medium containing 10% foetal calf serum [FCS], 
Sigma, St. Louis, MO, USA) and 2 mM glutamine (Gmax, Sigma) 
and incubated at 37
oC with 5% CO2 in 75 cm
2 flasks (TPP). For 
all dosing experiments, the medium was replaced with RPMI 
1640 containing 10% charcoal­stripped FCS (CSS, Hyclone) 
and 2 mM glutamine (Gmax) for 72 hours prior to treatment. 
All experiments were performed in triplicate on Ishikawa cells 
between passage number 3 and 15 and repeated three times.
2. Three dimensional (spheroid) cell culture 
An in vitro multicellular Ishikawa spheroid model was estab­
lished using a liquidoverlay technique. Briefly, semi­confluent 
monolayer cell cultures were trypsinized and single cells with 
100% vitality were cultured over 3% Noble agar­coated (Difco, 
Franklin Lakes, NJ, USA) six­well culture plates containing 5 mL 
RPMI­1640 medium at a concentration of 1×10
6 cells/well.
3. Experimental design
IM (IC50, 50 µM), LiCl (IC50, 100 µM), and MPA (IC50, 200 µM) 
and their combination were applied to monolayer and sphe­
roid cultures of estrogen­ and progesterone­ positive human Novel combinations of imatinib mesylate at endometrial carcinoma
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Ishikawa endometrium cells for 72 hours. The cell proliferation 
index, apoptotic index and cell cycle distributions by flow 
cytometry, morphology by scanning electron microscopy in 
monolayer cultures and cell ultrastructure by transmission 
electron microscopy (TEM) in three dimensional cultures were 
evaluated for 72 hours. Results were statistically analyzed us­
ing the Student’s t­test. 
4. Cell proliferation
The total cell number was counted by using an automated cell 
counter (NucleoCounter, ChemoMetec A/S, Allerod, Denmark). The 
starter kit which is com  pa    tible to cell counter and includes lysis 
buffer, stabilization buffer, nucleocasettes and software was 
used. Cells were harvested every 24 hours for 72 hours. Cells 
were pre­treated with lysis and stabilization buffers to dissolve 
cell aggregates and lyse cell membranes. Pre­treated cells were 
loaded to nucleocasettes which were coated with propidium 
iodid (PI) dye and their nuc  lei was stained with PI. Nucleoca­
settes were placed in device for 30­35 seconds to measure the 
PI fluorescence and then cell counts were analyzed with the 
software and recorded. 
5. Apoptotic index 
The apoptotic index was evaluated by using flow cytometric 
Annexin­V­fluorescein isothiocyanate/propidium iodide (An­
nexin­V­FITC/PI) staining. Following the instruction manual of 
the kit (BD Pharmingen, San Diego, CA, USA), briefly, cells were 
washed twice with PBS and resuspended by binding buffer 
containing 0.01 M HEPES, 0.14 mM NaCl, and 2.5 mM CaCl2. A 
cell suspension (1×10
5 cells in 100 µL) in binding buffer was 
incubated with 5 µL of FITC­labeled Annexin V (BD Pharmin­
gen) dye and PI for 15 minutes in the dark at room tempera­
ture. After incubation, the PI fluorescence and Annexin V were 
measured simultaneously in a BD FACS Calibur and analyzed 
with the instrument’s operating software (CellQuest: BD 
Pharmingen). Data acquisition and analysis were undertaken 
with CellQuest and WinMDI programs.
6. Caspase-3 levels
Caspase­3 levels in triplicate were analyzed using fluori­
metric kits (Sigma Aldrich, St. Louis, MO, USA). The caspase­3 
fluo  rimetric assay is based on the hydrolysis of the peptide 
substrate acetyl­Asp­Glu­Val­Asp­7­amido­4­methylcoumarin 
(Ac­DEVD­AMC) by caspase 3, resulting in the release of the 
fluorescent 7­amino­4­methylcoumarin (AMC) moiety. 1×10
4 
cells seeded in each well of 96 well plates washed twice in 
PBS and incubated in CHAPS lysis buffer at 4
oC for 20 minutes. 
We transfered 5 µL of cell lysate into the wells of other 96 well 
plates, then incubated with 5 µL of 2 mM Ac­DEVD­pNA pep­
tide substrate and 200 µL of assay buffer (HEPES 20 mM, pH 
7.4, CHAPS 0.1%, DTT 5 mM, EDTA 2 mM) at 37
oC for 1 hour in 
an incubator. The concentration of AMC released was quanti­
fied by reading in a fluorometer with a 360 nm excitation filter 
and 460 nm emission filter for optimal sensitivity. 
7. Cell cycle distributions
The effects of drugs on the cell cycle were examined using a 
DNA analysis kit (BD Pharmingen) according to the manufac­
turer’s instructions. Briefly, were induced at a cell density of 51
×10
5 cells/ml in the presence of each drug applied separately 
and in combination for different time intervals (24 and 72 hours). 
Ishikawa cells were harvested, centrifuged, washed and resus­
pended in buffer (dimethylsulfoxide in sucrose­sodium citrate) 
for 5 minutes at room temperature, respectively. A mixture of 
trypsin in spermine tetrahydrochloride detergent buffer was 
added and samples were incubated for 20 minutes at room 
temperature. After the addition of RNaseA and trypsin inhibi­
tor in spermine buffer, cells were incubated with propidium 
iodide, in dark, for 20 minutes at 4
oC. Finally, flow cytometric 
analysis was performed immediately using a Facscan flow cy­
to  meter (FACS Diva, Beckman­Dickinson, San Jose, CA, USA) 
and fluorescence intensity data were acquired using the in­
strument’s operating software (CellQuest). The percentages 
of the analyzed cell population in G0/G1­, S­ or G2/M­phases 
were determined by the Mod Fit cell­cycle analysis program.
8. Transmission electron microscopy
Harvested spheroids were fixed with 2.5% glutaraldehyde in 
0.1 M sodium cacodylate buffer and post­fixed in 1% osmium 
tetraoxide in 0.1 M sodium cacodylate buffer for 1 hour at 4
oC. Cells 
were incubatedin 1% uranyl acetate for 1 hour at 4
oC, dehyd­
rated in a graded acetone series and embedded in Epon 812. Sam­
ples were cut using a rotating blade microtome (Leica, Heer­
brugg, Switzerland) and 70 nm­thick sections were mounted 
on copper grids. Sections were subsequently stained with 5% 
uranyl acetate and counterstained with Reynold’s lead citrate. 
Sections were examined with a Jeol­Jem 1011 transmission 
electron microscope. Photographs were taken at several mag­
nifications.
9. Midkine levels
Cell culture supernatants were analyzed for midkine levels in 
triplicate using ELISA kits (PeproTech, Rocky Hill, NJ, USA). The 
lower detection limit of the assay was 150 pg/mL for midkine. 
Midkine levels were measured by an ELISA system in which 
polyclonal antihuman midkine was used as capture antibody 
(Peprotech). Detection was bybiotinylated polyclonal antihu­
man midkine antibody (PeproTech) followed by streptavidin Ayhan Bilir, et al.
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HRP (Sigma) and a TMB enzyme substrate system (Sigma). The 
reaction was stopped by 1 M H2SO4 and readings were made 
at 450 nm by a spectrometer (M2, Molecular devices, Sunny­
vale, CA, USA).
10. Statistical analysis and determination of synergism
SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) and Excel 2007 were 
used for the statistical analysis. All results were statistically 
analyzed using the Student’s t­test. Data were represented as 
mean±SE. A p<0.05 was considered significant. Synergy was 
determined as described previously [21]. Briefly, synergism 
was determined using the following formula: Combination 
index (CI): D1/(DX)1+D2/(DX)2 where D1 is tested concentra­
tion of IM used in combination with LiCl or MPA, D2 is the 
tested concentration of LiCl or MPA used in combination with 
IM, (DX)1 is the concentration of a singly applied IM and (DX)2 
is the concentration of a singly applied LiCl or MPA. A CI value 
of 1 indicates an additive effect, a CI value <1 indicates a syn­
ergistic effect and a CI value >1 indicates an antagonist effect. 
RESULTS
1. Cell proliferation
As shown in Fig. 1, all drug treatments decreased cell num­
bers (p<0.05). Singly applied drugs lost their efficiency in a 
time de  pendent manner, however the combination groups 
did not lose their efficiency and led to a high decrease in cell 
number for 72 hours (p<0.05). MPA and the combination of 
IM and MPA seemed to be the most efficient drug applica­
tions for 72 hours (p<0.05).
2. Apoptotic index 
Fig. 2 showed that all drug treatments increased the apop­
totic index (p<0.05). Apoptotic index of singly applied drugs 
decreased in a time dependent manner, but the apoptotic 
index induced by MPA was the highest (p<0.05). The combi­
nation groups induced higher apoptotic index than singly ap­
plied drugs and IM with MPA induced the highest apoptotic 
index (p<0.05).
3. Caspase-3 levels
Caspase­3 levels in Fig. 3 showed that all drug treatments 
Fig. 1. The effects of single and combined drugs on cell proliferation. 
Columns, average of six wells. Data are representative of separate three 
experiments. C, control; IM, imatinib mesylate; LiCl, lithium chloride; 
IM+LiCl, the combination of IM and LiCl; MPA, medroxyprogesterone 
acetate; IM+MPA, the combination of IM and MPA.
Fig. 2. The alterations in apoptotic index induced by different drug 
applications. Columns, average of six wells. Data are representative 
of separate three experiments. C, control; IM, imatinib mesylate; LiCl, 
lithium chloride; IM+LiCl, the combination of IM and LiCl; MPA, med­
roxyprogesterone acetate; IM+MPA, the combination of IM and MPA.
Fig. 3. Caspase­3 levels effected by single and combined drugs. Col­
umns, average of six wells. Data are representative of separate three 
experiments. C, control; IM, imatinib mesylate; LiCl, lithium chloride; 
IM+LiCl, the combination of IM and LiCl; MPA, med  roxy  pro  gesterone 
acetate; IM+MPA, the combination of IM and MPA.Novel combinations of imatinib mesylate at endometrial carcinoma
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increased apoptosis (p<0.05). The increase in caspase­3 levels 
were determined both at single and combined drug applica­
tions (p<0.05). The highest increase were determined at the 
combination groups (p<0.05). MPA and IM with MPA induced 
the highest caspase­3 levels (p<0.05). 
4. Cell cycle distributions
LiCl, MPA and the combination groups led to G0+G1 arrest 
at 24 hour except for IM. IM induced S­phase arrest at this 
time interval. However, all drug applications induced G0+G1 
arrest at 48 hours and 72 hours (Fig. 4). 
5. Midkine levels
Fig. 5 showed that all drug applications induced a decrease 
in MDK levels for 72 hours (p<0.05). Highest decrease was 
determined at IM combined with MPA and IM combined with 
LiCl, respectively for 72 hours (p<0.05). Among single applied 
drugs, IM induced highest decrease and the latter were MPA 
and then LiCl (p<0.05).
6. TEM
According to the TEM results in Fig. 6, the cells of the control 
group presented healthy morphology including intact cell mem­
brane with microvilli, cell junctions, intact nuclear membranes 
with the proportional spread euchromatin, the proportional 
distribution of nucleus and cytoplasm, mitochondria in a nor­
mal size with intact outer and inner cell membranes, cytoplas­
mic reticulums and ribosomes in a normal size. The intranucle­
ar channel formation and lipid vacuoles were determined in 
some cells of spheroids (Fig. 6A). After IM was applied, disrup­
ted cell mebranes, apparent cell apoptosis was observed, i.e. 
chromatins aggregated around nuclear membrane, intact 
nu
 clear membrane, vacuoles with unknown content, cell 
rem  nants were determined between intercellular area. Gaps 
were formed inside the spheroids due the loss of cell interrac­
tions (Fig. 6B). LiCl applied spheroids showed that intact cell 
and nuclear membranes, the loss of cell to cell interactions, 
lytic cytoplasm with many vacuoles with unknown content 
and autophagic vacuoles, many lipid vacuoles (Fig. 6C). The 
spheroids of the combination group IM with LiCl showed high 
apoptotic appearence, gaps inside spheroids due to the loss 
of cell interactions, severe mitochondri damage, i.e, swollen 
mitochondria with disrupted inner membranes, vacuoles. Some 
cells lost their cell membrane, consequently cell remnants 
can be determined in the intercellular area (Fig. 6D). MPA in­
duced the loss of cell interactions, apoptotic nucleus, many 
auotophagic and lipid vacuoles, swollen mitochondria with 
disrupted and/or lost inner membranes (Fig. 6E). No intact 
spheroid structure was determined in the combination of IM 
with MPA. High incidence of cell remnants were seen in the 
intercellular area. The morphological changes which were 
observed in rarely seen cells were listed as the loss of nucleus 
membranes, high apoptotic appearence, severe mitochondria 
damage with disrupted and/or lost outer and inner mem­
branes, and huge autophagic vacuoles (Fig. 6F).  
DISCUSSION
The Ishikawa human endometrial carcinoma cell line has both 
estrogen and progesteron receptors like type I endometrium 
Fig. 5. The effect of different drug applications on MDK levels. Col­
umns, average of six wells. Data are representative of separate three 
experiments. C, control; IM, imatinib mesylate; LiCl, lithium chloride; 
IM+LiCl, the combination of IM and LiCl; MPA, medroxyprogesterone 
acetate; IM+MPA, the combination of IM and MPA.
Fig. 4. The alterations of cell cycle distributions by different drug appli­
ca  tions. Columns, average of six wells. Data are representative of se  pa  rate 
three experiments. C, control; IM, imatinib mesylate; LiCl, lithium 
chlo  ride; IM+LiCl, the combination of IM and LiCl; MPA, med  roxypro­
gesterone acetate; IM+MPA, the combination of IM and MPA.Ayhan Bilir, et al.
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carcinoma [2]. We planned to prevent/inhibit estrogen effects 
by using a hormone MPA and a chemical LiCl. Both two differ­
ent treatments had common targets to inhibit estrogen effect. 
According to our results, we detected the highest efficiency in 
the single applied MPA and its combination with IM. Although 
single LiCl took third place in efficient inhibition among singly 
applied drugs and lost its effect much more than others as 
time advanced, its combination with IM was very effective and 
did not lose its effect in a time dependent manner.  
IM was the second effective drug after MPA among the 
single applied drugs in the present study. As documented be­
fore, the mitogenic action of estrogen in the endometrial can­
cer through growth factors and their receptors (EGFR, IGF­IR, 
c­MET) comprise the activation of two key signaling cascades 
as the PI3K/AKT and the RAS/RAF/MAPK pathways. In addi­
tion, it was proposed that both estrogen receptor alpha (ERα) 
Fig. 6. The alterations in cell ultrastructure by different drug applications. (A) Control (×7,500), (B) Imatinib mesylate (IM; ×10 k), (C) Lithium chloride 
(LiCl; ×6,000 and ×6,000), (D) IM+LiCl (×10 k and ×7,500), (E) Medroxyprogesterone acetate (MPA; ×7,500), (F) IM+MPA (×10 k and ×7,500). 
n, nucleus; nu, nucleolus; lp, lipid vacuole; mi, mitochondria; mv, microvillus; lt, lytic cytoplasm; j, junctions; v, vacuole; ch, chromatin; cr, cell 
remnants; *, apoptotic cell; av, autophagic vacuole; g, gaps.Novel combinations of imatinib mesylate at endometrial carcinoma
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and AKT play a double role as both downstream target and 
activate each other. AKT­mediated phosphorylation of ERα 
results in the transcriptional activation of ERα, independent 
of ligand binding [2]. IM may terminate one of the estrogen 
mediated mitogenic signalling through the inhibition of re­
ceptor tyrosine kinases in this study.
Flow cytometric apoptotic index, caspase­3 levels and ultra­
structure analysis showed that the reason for the cell prolifera­
tion inhibition and the disruption of spheroid structure was 
apoptotic cell death. However, ultrastructure analysis of MPA 
and its combination with IM gave additional information that 
the autophagic cell death may take part in their mechanism 
of action. In our previous study with MPA, the FM3A murine 
breast tumor cell line was treated with epirubicin alone and 
with MPA or tamoxifen, and we determined that all drugs in­
duced autophagy, but when tamoxifen combined with MPA 
autophagy was increased [22]. Different from single MPA, 
autophagic vacuoles which were observed in the combintion 
group were huge. In contrast to our previous studies in neuro­
logic tumours [23], no autophagic vacuoles were determined 
in the IM group. Recent reports mentioned that autophagy is 
a two­edged sword that can lead to cell survival or cell death 
(autophagic cell death). Orrenius et al. [24] suggested that 
there is a cross­talk between cell death modalities, and this 
means different signals can cause a shift from autophagy to 
apoptosis or apoptosis to autophagy, or a mixture of these 
two cell­death modes. In the light of the increased efficiency 
of the combination group, we suggest that autophagic vacu­
oles may belong to the autophagic cell death, which can exist 
at the same time with apoptotic cell death or can be pre­step 
for the apoptotic cell death.
Nishio et al. [14] treated two cases of multidrug­resistant re­
current endometrial cancer with MPA successfully. Although 
they accomplished complete response after surgical opera­
tion and post operative chemotherapy with MPA for endome­
trial cancer, they found lung and small intestine metastasis. 
Eventually, they performed surgical and postoperative therapy 
again. The combination of MPA with IM can treat both the pri­
mary tumor as endometrial cancer and metastic tumours as 
gastrointestinal stromal tumors (GISTs) etc. MPA can be used 
when the hormone receptor status are positive. In the present 
study, we also used LiCl without taking into consideration the 
estrogen and its receptor status to determine the treatment 
fate in MPA resistant tumours. The efficiency of LiCl with IM 
was also very effective in a time dependent manner similar to 
MPA with IM. It can be proposed that IM with LiCl can also be 
used effectively in MPA resistant tumours and their metastasis.
Rawnaq et al. [25] in serum of patients with GISTs and Erguven 
et al. [unpublished observation] in human glioblastoma cells 
in vitro showed that IM induced decrease in MDK levels. Con­
comitant with this study, in the present study we determined 
that IM decreased MDK levels and it was the most efficient 
group. Zhang et al. [20] examined the expression of the mRNA 
coding for seven polypeptide angiogenic factors in normal en­
dometrial epi  thelial, stromal and three endometrial carcinoma 
lines. The endo  metrial epithelial and stromal cells express 
mRNA for the poly  peptide angiogenic factors, basic fibro­
blast growth factor, vascular endothelial cell growth factor, 
transforming growth factor­beta 1 and pleiotrophin, as well as 
the cytokine midkine. They stimulated growth of normal en­
dometrial epithelial cells by 17­beta­oestradiol and epidermal 
growth factor. They determined that expression of the mRNA of 
both vascular endo  thelial growth factor and MDK in normal en­
dometrial epithelial cells showed a 2­fold increase after treat­
ment with a physiological dose of 17­beta­oestradiol (10
­10 M), 
while, in contrast, the mRNA of transforming growth factor­
beta 1 de  creased 4­fold after treatment with 17­beta­oestradi­
ol (10
­10 M) and was abolished by exposure to progesterone (5
×10
­9 M) [21]. In our study, concomitant with Zhang et al. [20], 
MPA decreased MDK levels efficiently after IM, and IM with 
MPA induced the highest decrease in MDK levels among all 
groups. As in our recent study in human neuroblastoma cell 
line named SH­SYSY [12], we determined that LiCl decreased 
MDK levels in Ishikawa human endometrium cancer cells and 
second highest decrease in MDK levels were determined with 
the combination of IM and LiCl. According to our results, it 
may be concluded that high MDK level decrease in combina­
tion groups were determined because of IMs’ highest activity. 
We concluded that LiCl and MPA potentiated the cyctotox­
icity of IM, and the inhibition of estrogens activity through 
growth factors including MDK, wnt/catenin pathway may be 
involved in termination of endometrial cancer defense. This 
multi­targeted therapies may provide treatment for resistant, 
metastatic and recurrent endometrial cancers with anorexia/
cachexia, physcotic disorders and contraception problems. 
Eventually, the treatment of cancer with/without complica­
tions with regained/increased life quality can be accom­
plished at the end of this protocol. Further investigations with 
different human endometrial carcinoma cell lines in vitro and 
in vivo are needed to start clinical trials.   
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